Fig. 2

dBET6 inhibits LD-induced retinal function impairment. A Schematic illustration shows the experimental design. Mice were i.p. injected with dBET6 (10 mg/kg) at 1 h before and 24 h after 2-h light exposure. WB analysis (B) and visual tests (C–G) were performed at 48 h post-LD. For mouse strain: B–D, BALB/cJ; E–G, C57BL/6J. B WB analysis shows degradation of BRD4 protein in mouse retinas with dBET6 treatment. C Representative dark-adapted ERG results. D Luminance-response results for the a- and b-waves. n = 8–10 mice, 16–20 eyes per group. ns not significant, # or *p < 0.05; ## or **p < 0.01; ### or ***p < 0.0005, ####: p < 0.0001 (#: Vehicle versus LD + Vehicle, *: LD + Vehicle versus LD + dBET6), two-way ANOVA, Tukey’s test. E Left: a captured image to illustrate the optomotor apparatus used in the study. The C57BL/6J mice were used in this study as described in the methods. Right: visual acuity measured as the spatial frequency threshold in mice of indicated treatment. *: p < 0.05, n = 6–7 mice per group, One-way ANOVA, Tukey’s test. F Representative dark-adapted ERG results performed on C57BL/6J mice. G Quantification results of a- and b-waves with indicated treatment on C57BL/6J mice. n = 4 mice, 6–8 eyes per group. # or *: p < 0.05; ##: p < 0.01; ###: p < 0.0005 (#: Vehicle versus LD + Vehicle, *: LD + Vehicle versus LD + dBET6), two-way ANOVA, Tukey’s test